A Novel Differentiated In Vivo Lentiviral Platform

• Analysis of the limitations in existing lentiviral systems identified engineering constraints that shaped the starting architecture for a new lentiviral platform, enabling clearer mechanistic differentiation 
• Preclinical proof of concept readouts and benchmarking data will be presented for the first time

Speakers:

Stefanos Theoharis

Chief Executive Officer

OneChain Immunotherapeutics